terameprocol profile

ID Source	ID
PubMed CID	476861
CHEMBL ID	90983
CHEBI ID	177824
SCHEMBL ID	194588
MeSH ID	M0206544

Synonym
em 1421
em-1421
CHEMBL90983
CHEBI:177824
4-[(2s,3r)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
meso-1,4-bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane
4-[(2s,3r)-4-(3,4-dimethoxyphenyl)-2,3-dimethyl-butyl]-1,2-dimethoxy-benzene
tmndga
terameprocol ,
terameprocol (inn/usan)
24150-24-1
D09014
butane, 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethyl-, meso-
meso-tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
53yet703f2 ,
meso-tetra-o-methylnordihydroguaiaretic acid
unii-53yet703f2
terameprocol [usan:inn]
tetramethyl ndga
NCGC00346832-01
4-[(2r,3s)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene
1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethyl-, meso-
terameprocol [who-dd]
1,1'-((2r,3s)-2,3-dimethylbutane-1,4-diyl)bis(3,4-dimethoxybenzene)
terameprocol [usan]
benzene, 4-((2r,3s)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl)-1,2-dimethoxy-, rel-
terameprocol [inn]
em1421
meso-tetra-o-methyl nordihydroguaiaretic acid
smr004701682
MLS006010717
SCHEMBL194588
tetramethylnordihydroguaiaretic acid
ORQFDHFZSMXRLM-IYBDPMFKSA-N
terameprocol, >=98% (hplc)
J-015367
benzene,4-[(2r,3s)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxy-,rel-
DB12226
(2r,3s)-2,3-dimethyl-1,4-bis(3,4-bimethoxylphenyl)-butane
rel-4,4'-((2r,3s)-2,3-dimethylbutane-1,4-diyl)bis(1,2-dimethoxybenzene)
tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
Q27261142
MS-25644
CS-0002608
tetramethyl-nordihydroguaiaretic acid
HY-10447

Excerpt	Reference	Relevance
" There were no serious adverse events (SAEs) and possible treatment-related Adverse Events (AEs) reported were mild and self-limiting."	( Phase I/II clinical safety studies of terameprocol vaginal ointment. Arnold, S; Dalby, R; Frazer, N; Khanna, N; Stern, J; Tan, M, 2007)	0.34

Excerpt	Reference	Relevance
"The ability of Tetra-O-methyl nordihydroguaiaretic acid (M4N) to induce rapid cell death in combination with Etoposide, Rapamycin, or UCN-01 was examined in LNCaP cells, both in cell culture and animal experiments."	( Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. Huang, RC; Kimura, K, 2016)	0.43

Excerpt	Reference	Relevance
" administration to ICR mice indicated an absolute bioavailability for oral M4N of approximately 88%."	( Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Chang, CC; Chung, Y; Henry, RA; Huang, RC; Liang, YC; Lin, E; Mold, DE; Park, R, 2005)	0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
lignan	Any phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	0.8333	0.0030	8.7949	48.0869	AID1347053
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	1.8999	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	1.1044	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
G	Vesicular stomatitis virus	Potency	3.0112	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	16.9330	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	0.8333	0.0030	8.7949	48.0869	AID1347053
Interferon beta	Homo sapiens (human)	Potency	3.0112	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	3.0112	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	3.0112	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	3.0112	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (173)

Assay ID	Title	Year	Journal	Article
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID433936	Cytotoxicity against human MCF7 cells after 5 days by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID549510	Cytotoxicity against human LNCAP cells after 3 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID740515	Inhibitive ratio of growth metabolism of human K562 cells at 2 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232901	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 5 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID549511	Cytotoxicity against human HT-29 cells after 3 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID740512	Inhibitive ratio of growth metabolism of human K562 cells at 5 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740532	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 240 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740513	Inhibitive ratio of growth metabolism of human K562 cells at 4 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740517	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 6 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID227432	Inhibition ratio of human reticulocyte 15-lipoxygenase (15-HLO)/ human platelet 12-lipoxygenase (12-HLO); NI is no inhibition	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID433935	Cytotoxicity against human HT-29 cells after 5 days by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID232898	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 2 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID46497	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 100 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID111579	Percent Change in body weight of 5 mice when intraperitoneally administered daily once for 1 day at dose 300 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID232906	Relative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 1 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740533	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 160 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID2923	Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID1464091	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of mycobacterial growth incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID433950	Cytotoxicity against human ACC375 cells	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID740529	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 20 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID46498	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 10 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID1464077	Antibacterial activity against carbapenem-resistant Acinetobacter baumannii (12-666) assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID433937	Cytotoxicity against human HepG2 cells after 5 days by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID217597	Comparative Potency (IC50s) at HSV-1 passage 10 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740521	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 2 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740510	Inhibitive ratio of growth metabolism of human K562 cells at 8 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID549509	Cytotoxicity against human Hep3B cells after 3 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID740534	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 80 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID780271	Cytotoxicity against human 786-0 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID433941	Cytotoxicity against human A375 cells assessed as inhibition of protein synthesis at 50 uM	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1464079	Antibacterial activity against oxacillin-resistant Escherichia coli OXA-48 assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID232900	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 4 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433955	Cell cycle arrest in human ACC375 cells assessed as accumulation at G2/M phase	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1464082	Antibacterial activity against extended-spectrum beta-lactamase-positive Klebsiella pneumoniae (14-2081) assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID217598	Comparative Potency (IC50s) at HSV-1 passage 2 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433949	Cytotoxicity against human A375 cells	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID429824	Cytotoxicity against human C8166 cells by MTT assay	2009	Journal of natural products, Jun, Volume: 72, Issue:6	Lignans with anti-HIV activity from Schisandra propinqua var. sinensis.
AID780270	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID1464093	Antimycobacterial activity against isoniazid/rifampicin/streptomycin-resistant Mycobacterium tuberculosis G133 assessed as inhibition of mycobacterial growth incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID780272	Cytotoxicity against human T47D cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID3071	percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID46499	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 1 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID1464081	Antibacterial activity against NDM-1 positive Klebsiella pneumoniae (14-3335) assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID740502	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 6 mg/L after 18 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 277.9 +/-1.4%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740527	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 80 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740519	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 4 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740530	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 380 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID549513	Cytotoxicity against human NCI/ADR-RES cells after 3 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID740536	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 20 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232905	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 9 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID1464095	Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as inhibition of mycobacterial growth up to 50 ug/ml incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID740511	Inhibitive ratio of growth metabolism of human K562 cells at 6 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232907	Relative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 2 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID217599	Comparative Potency (IC50s) at HSV-1 passage 3 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433940	Cytotoxicity against human A375 cells assessed as inhibition of RNA synthesis at 50 uM	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID740506	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 6 mg/L after 12 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 668.2 +/-0.8%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740507	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 4 mg/L after 12 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 668.2 +/-0.8%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232902	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 6 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID232903	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 7 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID780273	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID3113	percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID740504	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 6 mg/L after 18 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 788.8 +/-1.0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID780268	Cytotoxicity against human U87 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID740505	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 4 mg/L after 18 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 788.8 +/-1.0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID549512	Cytotoxicity against human MCF7 cells after 3 days by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID232908	Relative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 3 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID1464080	Antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa (13-1391) assessed as inhibition of microbial growth up to 50 ug/ml incubated for 48 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID232896	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 1 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID1464084	Antibacterial activity against trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID740516	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 8 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID217604	Comparative Potency (IC50s) at HSV-1 passage 8 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433939	Cytotoxicity against human A375 cells assessed as inhibition of DNA synthesis in at 50 uM	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID212040	Mortality in 5 mice when intraperitoneally administered daily once for 7 days at dose 50 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID217607	Comparative Potency (IC50s) at HSV-2 passage 2 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433951	Cytotoxicity against human ACC375 cells assessed as inhibition of DNA synthesis at 50 uM after 1 hr	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID433952	Cytotoxicity against human ACC375 cells assessed as inhibition of DNA synthesis at 50 uM after 24 hrs relative to control	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID549514	Solubility of the compound in water	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Glycosylated nordihydroguaiaretic acids as anti-cancer agents.
AID740524	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 320 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID46503	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 60 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID740526	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 160 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID217600	Comparative Potency (IC50s) at HSV-1 passage 4 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID46502	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 3 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID740523	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 380 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID46496	Inhibitory activity against HIV Tat-regulated Transactivation in COS cells.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID232904	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 8 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740535	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 40 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID433954	Cell cycle arrest in human ACC375 cells assessed as accumulation at G1/G0 phase	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID740522	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID217603	Comparative Potency (IC50s) at HSV-1 passage 7 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID1464078	Antibacterial activity against extended-spectrum beta-lactamase-positive Escherichia coli (14-2081) assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID740525	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 240 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232909	Relative safety was expressed as Selective index (TC50/IC50) at HSV-2 passage 4 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID46500	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 20 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID429825	Antiviral activity against HIV1 3B in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity	2009	Journal of natural products, Jun, Volume: 72, Issue:6	Lignans with anti-HIV activity from Schisandra propinqua var. sinensis.
AID780269	Cytotoxicity against human T98G cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID212039	Mortality in 5 mice when intraperitoneally administered daily once for 7 days at dose 25 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID212168	Mortality in 5 mice when intraperitoneally administered daily twice for 5 days at dose 50 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740503	Induction of apoptosis in human K562 cells assessed as mitochondrial transmembrane potential at 4 mg/L after 24 hrs by Rh123 staining based fluorescence spectrophotometer analysis (Rvb = 277.9 +/-1.4%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID1464092	Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis G122 assessed as inhibition of mycobacterial growth incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID46501	Compound tested for inhibition of HIV Tat-regulated Transactivation in COS cells at a concentration of 30 uM.	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.
AID1464096	Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis G122 assessed as inhibition of mycobacterial growth up to 50 ug/ml incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID217602	Comparative Potency (IC50s) at HSV-1 passage 6 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433938	Cytotoxicity against human A375 cells after 5 days by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID429826	Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B	2009	Journal of natural products, Jun, Volume: 72, Issue:6	Lignans with anti-HIV activity from Schisandra propinqua var. sinensis.
AID740509	Inhibition of growth metabolism of human K562 cells at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID212038	Mortality in 5 mice when intraperitoneally administered daily once for 7 days at dose 100 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID217717	Comparative Potency (IC50s) at HSV-2 passage 4 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740520	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 3 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID1464083	Antibacterial activity against NDM-1 positive Providencia rettgeri assessed as inhibition of microbial growth up to 50 ug/ml incubated for 24 hrs by microdilution assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID1464097	Antimycobacterial activity against isoniazid/rifampicin/streptomycin-resistant Mycobacterium tuberculosis G133 assessed as inhibition of mycobacterial growth up to 50 ug/ml incubated for 2 weeks by MABA method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.
AID232897	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 10 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID433953	Toxicity in ip dosed mouse	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID217605	Comparative Potency (IC50s) at HSV-1 passage 9 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID217606	Comparative Potency (IC50s) at HSV-2 passage 1 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740528	Inhibitive ratio of growth metabolism of Schizosaccharomyces pombe ACCC 20047 at 40 mg/L at 32 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID740531	Inhibition of growth metabolism of Schizosaccharomyces pombe ACCC 20047 assessed as growth rate constant at 320 mg/L at 32 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID232899	Relative safety was expressed as Selective index (TC50/IC50) at HSV-1 passage 3 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740514	Inhibitive ratio of growth metabolism of human K562 cells at 3 mg/L at 37 degC by TAM air microcalorimetry (Rvb = 0%)	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID111580	Percent Change in body weight of 5 mice when intraperitoneally administered daily once for 7 days at dose 50 mg/kg	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740518	Inhibition of growth metabolism of human K562 cells assessed as growth rate constant at 5 mg/L at 37 degC by TAM air microcalorimetry	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID217608	Comparative Potency (IC50s) at HSV-2 passage 3 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID740508	Induction of late apoptosis in human K562 cells assessed as cell membrane structural changes, smaller nuclear size, chromatin assembly under nuclear envelope, clear nuclear membrane structure, lipid droplets in cytoplasm, protruded cell surface with red n	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
AID217601	Comparative Potency (IC50s) at HSV-1 passage 5 in vero cells	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (6.52)	18.2507
2000's	14 (30.43)	29.6817
2010's	19 (41.30)	24.3611
2020's	10 (21.74)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	4 (8.70%)	5.53%
Reviews	3 (6.52%)	6.00%
Case Studies	1 (2.17%)	4.05%
Observational	0 (0.00%)	0.25%
Other	38 (82.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.03	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.73	3	0	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	2.11	1	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide [no description available]	2.58	2	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.05	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
thiazoles [no description available]	2.15	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
monocrotaline Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.	2.15	1	0	pyrrolizidine alkaloid
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	3.35	1	0	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	2.15	1	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.05	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.03	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.52	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
masoprocol Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.. masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase.	10.29	32	4	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
7-hydroxystaurosporine [no description available]	2.13	1	0
diphyllin diphyllin: extract of Cleistanthus collinus (Roxb), a highly poisonous plant; do not confuse with diphyllin or diphylline which is the main heading AMINOPHYLLINE; do not confuse with the theophylline derivative DYPHYLLINE	3.35	1	0	lignan
galgravin galgravin: an anti-PAF constituent from the stems of Piper futokadsura, the Chinese drug haifengteng; structures of the isomers galgravin, galbelgin (10569-12-7) and veraguensin (19950-55-1) given in first source; RN given refers to galgravin, the (2alpha,3beta,4beta,5alpha)-isomer. galgravin : A member of the class of aryltetrahydrofurans carrying two 3,4-dimethoxyphenyl substituents at positions 2 and 5 as well as two methyl groups at positions 3 and 4.	2.05	1	0	aryltetrahydrofuran; dimethoxybenzene; lignan; ring assembly	bone density conservation agent; neuroprotective agent; plant metabolite; platelet aggregation inhibitor
3'-o-methyl-nordihydroguaiaretic acid heminordihydroguaiaretic acid: RN given refers to cpd without isomeric designation; structure given in first source	1.99	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	2.15	1	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
kadsurin kadsurin: from the stems of Kadsura heteroclita; has anti-lipid peroxidative effect; cinnamate dimer similar to schisanhenol of Schisandra	2.05	1	0	tannin	metabolite
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	3.35	1	0
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.03	1	0	cyclodextrin
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.05	1	0	actinomycin	mutagen
meso-dihydroguaiaretic acid meso-dihydroguaiaretic acid : A lignan that is 2,3-dimethylbutane substituted by 2-methoxyphenol groups at positions 1 and 4 respectively. It has been isolated from the bark of Machilus robusta.	2.73	3	0	guaiacols; lignan	plant metabolite
fatostatin fatostatin: inhibits activation of SREBP; structure in first source	2.15	1	0	thiazoles
phillygenin phillygenin: cytoprotective lignan from Forsythia suspensa; structure in first source	3.35	1	0
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.15	1	0
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2.41	1	0	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
thromboxane a2 Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation.	2.41	1	0	epoxy monocarboxylic acid; thromboxanes A	mouse metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.13	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
everolimus [no description available]	7.17	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
staurosporine staurosporinium : Conjugate acid of staurosporine.	2.13	1	0	ammonium ion derivative
bicyclol bicyclol: an antihepatitis drug, on the metabolism and hepatotoxicity of aflatoxin B1 (AFB1) in rats.	3.35	1	0
sepantronium sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.	2.15	1	0	organic cation
machilin a machilin A: stimulates osteoblast differentiation; isolated from Myristica fragrans; structure in first source	2.05	1	0
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.6	1	0	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
pf-429242 PF-429242: a subtilisin kexin isozyme-1/site-1 protease inhibitor	2.15	1	0
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	1.99	1	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	2.08	1	0	dacarbazine

Condition	Indicated	Relationship Strength	Studies	Trials
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	1.99	1	0
Malignant Melanoma [description not available]	0	2.43	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	0	2.43	2	0
Hepatocellular Carcinoma [description not available]	0	2.06	1	0
Cancer of Liver [description not available]	0	2.06	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.06	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.06	1	0
Congenital Zika Syndrome [description not available]	0	2.59	2	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.59	2	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.59	2	0
Brucella Infection [description not available]	0	2.41	1	0
Brucellosis Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.	0	2.41	1	0
Astrocytoma, Grade IV [description not available]	0	2.58	2	0
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	0	2.58	2	0
Encephalitis, West Nile Fever [description not available]	0	2.15	1	0
West Nile Fever A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71)	0	2.15	1	0
Cancer of Endometrium [description not available]	0	2.17	1	0
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	0	2.17	1	0
Leucocythaemia [description not available]	0	3.5	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	8.5	1	1
Leukemia, Lymphoblastic, Acute, T Cell [description not available]	0	2.11	1	0
Leukemia, Pre-B-Cell [description not available]	0	2.11	1	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	2.11	1	0
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.	0	2.11	1	0
Benign Neoplasms [description not available]	0	3.38	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	5.38	2	0
Cardiac Remodeling, Ventricular [description not available]	0	2.15	1	0
Pulmonary Arterial Remodeling [description not available]	0	2.15	1	0
Blood Pressure, High [description not available]	0	2.15	1	0
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	0	7.15	1	0
Cancer of Intestines [description not available]	0	2.15	1	0
Cancer of Pancreas [description not available]	0	2.15	1	0
Cancer of Stomach [description not available]	0	2.15	1	0
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	0	2.15	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	0	2.15	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	0	2.15	1	0
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	0	2.15	1	0
Infections, Poxviridae [description not available]	0	2.05	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.06	1	0
Cancer of Lung [description not available]	0	2.43	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.06	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.43	2	0
Extranodal NK-T-Cell Lymphoma [description not available]	0	2.06	1	0
Cancer of Nose [description not available]	0	2.06	1	0
B16 Melanoma [description not available]	0	2.43	2	0
Kahler Disease [description not available]	0	2.06	1	0
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	0	2.06	1	0
Disease Exacerbation [description not available]	0	4.75	2	1
Benign Neoplasms, Brain [description not available]	0	4.79	2	1
Glial Cell Tumors [description not available]	0	4.37	1	1
Local Neoplasm Recurrence [description not available]	0	4.37	1	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	0	4.79	2	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1	11.37	1	1
Adenocarcinoma, Basal Cell [description not available]	0	2.42	2	0
Barrett Epithelium [description not available]	0	2.02	1	0
Cancer of Esophagus [description not available]	0	2.02	1	0
Condition, Preneoplastic [description not available]	0	2.02	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	2.42	2	0
Barrett Esophagus A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.	0	2.02	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	0	2.02	1	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	0	2.02	1	0
Experimental Neoplasms [description not available]	0	2.42	2	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	0	2.94	1	0
HPV Infection [description not available]	0	3.42	1	1
Cervix Dysplasia [description not available]	0	3.42	1	1
Cancer of Cervix [description not available]	0	3.42	1	1
Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE.	0	3.42	1	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	0	3.42	1	1
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	0	3.42	1	1
Sexually Transmitted Disease, Viral [description not available]	0	3.43	1	1
Breast Cancer [description not available]	0	2	1	0
Cancer of Colon [description not available]	0	2	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	0	2	1	0

terameprocol

Cross-References

Synonyms (46)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Biological Processes (45)

Molecular Functions (18)

Ceullar Components (22)

Bioassays (173)

Research

Studies (46)

Study Types

terameprocol

Cross-References

Synonyms (46)

Research Excerpts

Toxicity

Compound-Compound Interactions

Bioavailability

Drug Classes (1)

Protein Targets (10)

Potency Measurements

Biological Processes (45)

Molecular Functions (18)

Ceullar Components (22)

Bioassays (173)

Research

Studies (46)

Study Types

Related Drugs (38)

Related Conditions (74)